This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Optimer Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Stocks in this article: OPTR

Clearly, we have exceeded expectations for the first year after launch. Looking more closely at the second quarter, demand for DIFICID continue to grow. Ex-factory gross sales grew from $16.4 million to $18 million, an increase of over 9%. Ex-wholesaler sales grew by 11%. Net sales grew by 6% as discounts expanded the gross to net from 12.6% to 15.2% as a result of new contracts with group purchasing organizations, expanded coverage from providers and the impact of the Medicare Part D coverage gap, commonly referred to as the donut hole. Given the success we are seeing across all payors channels where Optimer contract, especially Medicare Part D, where we not only contract with the actual payors but also incur liabilities related to the Medicare Part D doughnut hole, and institutional care settings where Optimer also make contract, such as long-term care. We expect that our projected gross to net will moderately -- will be moderately higher than the 15% range previously guided.

Given that demand in this setting is continuing to mature, we're hesitant at this point to give a specific number. Ex-factory growth was affected by a quarter end decrease in inventory levels at the wholesalers, which led to a softer than expected June. This trend was the opposite of what happened in quarter 1 when ex-factory net sales grew by 21%, while ex-wholesalers sale grew by 19%.

In the first 4 weeks of July, we experienced a growth of 13% in the average exposure of demand when compared to the June weekly average demand regaining momentum.

I believe, we continue to make significant progress in executing an impactful launch. As one would expect, we have learned a lot about C. diff and how hospitals treat it.

Our flexibility and nimbleness to rapidly adapt to the market, as well as DIFICID's profile and the need for a new and innovative medicine to combat C. diff will allow us to continue to help patients execute an impactful launch and build value for our shareholders.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs